Modern Subunit Vaccines: Development, Components, and Research Opportunities

TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties

Mosmann, T. R., & Coffman, R. L. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.001045 · Cited by 7,692

A Toll-like receptor recognizes bacterial DNA

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491

Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129

IL-17 and th17 cells

Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658

CpG motifs in bacterial DNA trigger direct B-cell activation

Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034

The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

Park, B. S., Song, D. H., Kim, H. M., Choi, B.-S., Lee, H., & Lee, J.-O. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,428

Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection

Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., Philpott, D. J., & Sansonetti, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200651200 · Cited by 2,408

Janeway's Immunobiology

Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258

Pathogen Recognition by the Innate Immune System

Kumar, H., Kawai, T., & Akira, S. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2010.529976 · Cited by 2,257

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106

Vaccine Adjuvants: Putting Innate Immunity to Work

Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924

Cross-presentation by dendritic cells

Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012) · Nature Reviews Immunology · doi:10.1038/nri3254 · Cited by 1,637

Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid–inducible gene-I and melanoma differentiation–associated gene 5

Kato, H., Takeuchi, O., Mikamo-Satoh, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T. S., Fujita, T., & Akira, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080091 · Cited by 1,599

Nod1 Detects a Unique Muropeptide from Gram-Negative Bacterial Peptidoglycan

Girardin, S. E., Boneca, I. G., Carneiro, L. A. M., Antignac, A., Jéhanno, M., Viala, J., Tedin, K., Taha, M.-K., Labigne, A., Zäthringer, U., et al. (2003) · Science · doi:10.1126/science.1084677 · Cited by 1,577

Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

Bauer, S., Kirschning, C. J., Häcker, H., Redecke, V., Hausmann, S., Akira, S., Wagner, H., & Lipford, G. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161293498 · Cited by 1,533

Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide

Jin, M. S., Kim, S. E., Heo, J. Y., Lee, M. E., Kim, H. M., Paik, S.-G., Lee, H., & Lee, J.-O. (2007) · Cell · doi:10.1016/j.cell.2007.09.008 · Cited by 1,344

Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins

Takeuchi, O., Sato, S., Horiuchi, T., Hoshino, K., Takeda, K., Dong, Z., Modlin, R. L., & Akira, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.10 · Cited by 1,329

Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance

Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M. C., & Steinman, R. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021598 · Cited by 1,306

Discrimination of bacterial lipoproteins by Toll-like receptor 6

Takeuchi, O., Kawai, T., Mühlradt, P. F., Morr, M., Radolf, J. D., Zychlinsky, A., Takeda, K., & Akira, S. (2001) · International Immunology · doi:10.1093/intimm/13.7.933 · Cited by 1,232

TICAM-1, an adaptor molecule that participates in Toll-like receptor 3–mediated interferon-β induction

Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., & Seya, T. (2003) · Nature Immunology · doi:10.1038/ni886 · Cited by 1,207

CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO

Trombetta, E. S., & Mellman, I. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104538 · Cited by 1,173

The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A Virus through Recognition of Viral RNA

Allen, I. C., Scull, M. A., Moore, C. B., Holl, E. K., McElvania-TeKippe, E., Taxman, D. J., Guthrie, E. H., Pickles, R. J., & Ting, J. P.-Y. (2009) · Immunity · doi:10.1016/j.immuni.2009.02.005 · Cited by 1,113

Immunological mechanisms of vaccination

Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089

Total chemical synthesis of proteins

Kent, S. B. H. (2009) · Chem. Soc. Rev. · doi:10.1039/b700141j · Cited by 922

Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland

Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030595 · Cited by 916

The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4

Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896

CpG DNA as a vaccine adjuvant

Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., & Klinman, D. M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.174 · Cited by 891

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

Smith, K. D., Andersen-Nissen, E., Hayashi, F., Strobe, K., Bergman, M. A., Barrett, S. L. R., Cookson, B. T., & Aderem, A. (2003) · Nature Immunology · doi:10.1038/ni1011 · Cited by 808

Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer

Kang, J. Y., Nan, X., Jin, M. S., Youn, S.-J., Ryu, Y. H., Mah, S., Han, S. H., Lee, H., Paik, S.-G., & Lee, J.-O. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.018 · Cited by 765

Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA

Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733

TLR3: Interferon induction by double-stranded RNA including poly(I:C)☆

MATSUMOTO, M., & SEYA, T. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.005 · Cited by 685

Janeway’s Immunobiology

Soesatyo, M. H. (2012) · Jurnal Teknosains · doi:10.22146/teknosains.5992 · Cited by 652

Carbohydrate vaccines: developing sweet solutions to sticky situations?

Astronomo, R. D., & Burton, D. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3012 · Cited by 629

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., & Rock, K. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4942 · Cited by 591

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587

Structural Basis of TLR5-Flagellin Recognition and Signaling

Yoon, S.-I., Kurnasov, O., Natarajan, V., Hong, M., Gudkov, A. V., Osterman, A. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1215584 · Cited by 582

Covalent lipoprotein from the outer membrane of Escherichia coli

Braun, V. (1975) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(75)90013-1 · Cited by 580

Reverse Vaccinology: Developing Vaccines in the Era of Genomics

Sette, A., & Rappuoli, R. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.017 · Cited by 559

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides

Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A., et al. (1994) · Immunity · doi:10.1016/s1074-7613(94)80017-0 · Cited by 523

A self-assembling peptide acting as an immune adjuvant

Rudra, J. S., Tian, Y. F., Jung, J. P., & Collier, J. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912124107 · Cited by 523

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., Himanen, S.-L., Hublin, C., Julkunen, I., Olsén, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033536 · Cited by 498

Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa

Khader, S. A., Gaffen, S. L., & Kolls, J. K. (2009) · Mucosal Immunology · doi:10.1038/mi.2009.100 · Cited by 481

The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement

Caminschi, I., Proietto, A. I., Ahmet, F., Kitsoulis, S., Shin Teh, J., Lo, J. C. Y., Rizzitelli, A., Wu, L., Vremec, D., van Dommelen, S. L. H., et al. (2008) · Blood · doi:10.1182/blood-2008-05-155176 · Cited by 480

Molecular programming of B cell memory

McHeyzer-Williams, M., Okitsu, S., Wang, N., & McHeyzer-Williams, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3128 · Cited by 449

Cutting Edge: Activation of Toll-Like Receptor 2 Induces a Th2 Immune Response and Promotes Experimental Asthma

Redecke, V., Häcker, H., Datta, S. K., Fermin, A., Pitha, P. M., Broide, D. H., & Raz, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2739 · Cited by 448

Accessory molecules for Toll-like receptors and their function

Lee, C. C., Avalos, A. M., & Ploegh, H. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3151 · Cited by 439

Use of defined TLR ligands as adjuvants within human vaccines

Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437

Recent advances in the discovery and delivery of vaccine adjuvants

O'Hagan, D. T., & Valiante, N. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1176 · Cited by 434

Stapled Peptides for Intracellular Drug Targets

Verdine, G. L., & Hilinski, G. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00001-x · Cited by 433

Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles

Shen, H., Ackerman, A. L., Cody, V., Giodini, A., Hinson, E. R., Cresswell, P., Edelson, R. L., Saltzman, W. M., & Hanlon, D. J. (2006) · Immunology · doi:10.1111/j.1365-2567.2005.02268.x · Cited by 420

Bacterial DNA causes septic shock

Sparwasser, T., Miethke, T., Lipford, G., Borschert, K., Häcker, H., Heeg, K., & Wagner, H. (1997) · Nature · doi:10.1038/386336a0 · Cited by 411

Flagellin as an Adjuvant: Cellular Mechanisms and Potential

Mizel, S. B., & Bates, J. T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002156 · Cited by 399

A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules

Sinigaglia, F., Guttinger, M., Kilgus, J., Doran, D. M., Matile, H., Etlinger, H., Trzeciak, A., Gillessen, D., & Pink, J. R. L. (1988) · Nature · doi:10.1038/336778a0 · Cited by 384

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

Huleatt, J. W., Nakaar, V., Desai, P., Huang, Y., Hewitt, D., Jacobs, A., Tang, J., McDonald, W., Song, L., Evans, R. K., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.10.062 · Cited by 382

Designing Vaccines Based on Biology of Human Dendritic Cell Subsets

Palucka, K., Banchereau, J., & Mellman, I. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.007 · Cited by 332

Structural Biology of the Toll-Like Receptor Family

Kang, J. Y., & Lee, J.-O. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052909-141507 · Cited by 331

Mannose receptor‐mediated uptake of antigens strongly enhances HLA class II‐restricted antigen presentation by cultured dendritic cells

Tan, M. C. A. A., Mommaas, A. M., Drijfhout, J. W., Jordens, R., Onderwater, J. J. M., Verwoerd, D., Mulder, A. A., van der Heiden, A. N., Scheidegger, D., Oomen, L. C. J. M., et al. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270942 · Cited by 325

Alum adjuvant: some of the tricks of the oldest adjuvant

Kool, M., Fierens, K., & Lambrecht, B. N. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.038943-0 · Cited by 318

Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

Schutze, M. P., Leclerc, C., Jolivet, M., Audibert, F., & Chedid, L. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2319 · Cited by 304

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

Huleatt, J. W., Jacobs, A. R., Tang, J., Desai, P., Kopp, E. B., Huang, Y., Song, L., Nakaar, V., & Powell, T. J. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.08.013 · Cited by 299

Toll-like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease

Reynolds, J. M., Pappu, B. P., Peng, J., Martinez, G. J., Zhang, Y., Chung, Y., Ma, L., Yang, X. O., Nurieva, R. I., Tian, Q., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.010 · Cited by 299

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294

Therapeutic Cancer Vaccines: Current Status and Moving Forward

Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282

A 2020 vision for vaccines against HIV, tuberculosis and malaria

Rappuoli, R., & Aderem, A. (2011) · Nature · doi:10.1038/nature10124 · Cited by 273

A Modified Polyriboinosinic-Polyribocytidylic Acid Complex That Induces Interferon in Primates

Levy, H. B., Baer, G., Baron, S., Buckler, C. E., Gibbs, C. J., Iadarola, M. J., London, W. T., & Rice, J. (1975) · Journal of Infectious Diseases · doi:10.1093/infdis/132.4.434 · Cited by 270

Experimental human challenge infections can accelerate clinical malaria vaccine development

Sauerwein, R. W., Roestenberg, M., & Moorthy, V. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2902 · Cited by 267

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

Cho, H. J., Takabayashi, K., Cheng, P.-M., Nguyen, M.-D., Corr, M., Tuck, S., & Raz, E. (2000) · Nature Biotechnology · doi:10.1038/75365 · Cited by 258

Vaccines: the Fourth Century

Plotkin, S. A. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00290-09 · Cited by 256

TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides

Buwitt-Beckmann, U., Heine, H., Wiesmüller, K.-H., Jung, G., Brock, R., Akira, S., & Ulmer, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512525200 · Cited by 255

Recombinant protein vaccines produced in insect cells

Cox, M. M. J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.016 · Cited by 223

Computational Design of Epitope-Scaffolds Allows Induction of Antibodies Specific for a Poorly Immunogenic HIV Vaccine Epitope

Correia, B. E., Ban, Y.-E. A., Holmes, M. A., Xu, H., Ellingson, K., Kraft, Z., Carrico, C., Boni, E., Sather, D. N., Zenobia, C., et al. (2010) · Structure · doi:10.1016/j.str.2010.06.010 · Cited by 218

Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge

Mohamadzadeh, M., Duong, T., Sandwick, S. J., Hoover, T., & Klaenhammer, T. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900029106 · Cited by 210

Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists

Black, M., Trent, A., Tirrell, M., & Olive, C. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.160 · Cited by 203

Cutting Edge: TLR2 Directly Triggers Th1 Effector Functions

Imanishi, T., Hara, H., Suzuki, S., Suzuki, N., Akira, S., & Saito, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6715 · Cited by 200

Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold ‘em, knowing when to fold ‘em

Hutchings, M. I., Palmer, T., Harrington, D. J., & Sutcliffe, I. C. (2009) · Trends in Microbiology · doi:10.1016/j.tim.2008.10.001 · Cited by 196

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Apostolopoulos, V, Pietersz, G. A., Loveland, B. E., Sandrin, M. S., & McKenzie, I. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10128 · Cited by 189

A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors

Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P., & Levine, A. S. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.599 · Cited by 189

Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses

Alexander, J., del Guercio, M.-F., Maewal, A., Qiao, L., Fikes, J., Chesnut, R. W., Paulson, J., Bundle, D. R., DeFrees, S., & Sette, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.3.1625 · Cited by 188

CpG Still Rocks! Update on an Accidental Drug

Krieg, A. M. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0340 · Cited by 187

Immunization with HIV-1 Gag Protein Conjugated to a TLR7/8 Agonist Results in the Generation of HIV-1 Gag-Specific Th1 and CD8+ T Cell Responses

Wille-Reece, U., Wu, C.-Y., Flynn, B. J., Kedl, R. M., & Seder, R. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7676 · Cited by 185

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants

Shanmugam, A., Rajoria, S., George, A. L., Mittelman, A., Suriano, R., & Tiwari, R. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030839 · Cited by 180

Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines

Demento, S. L., Siefert, A. L., Bandyopadhyay, A., Sharp, F. A., & Fahmy, T. M. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.02.004 · Cited by 176

Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells

Khan, S., Bijker, M. S., Weterings, J. J., Tanke, H. J., Adema, G. J., van Hall, T., Drijfhout, J. W., Melief, C. J. M., Overkleeft, H. S., van der Marel, G. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701705200 · Cited by 175

CpG-DNA aided cross-presentation of soluble antigens by dendritic cells

Maurer, T., Heit, A., Hochrein, H., Ampenberger, F., O’Keeffe, M. A., Bauer, S., Lipford, G. B., Vabulas, R. M., & Wagner, H. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200208)32:8<2356::aid-immu2356>3.0.co;2-z · Cited by 174

Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction

Smirnov, D., Schmidt, J. J., Capecchi, J. T., & Wightman, P. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.061 · Cited by 174

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)

Weeratna, R. D., Makinen, S. R., McCluskie, M. J., & Davis, H. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.024 · Cited by 170

Mouse and human intestinal immunity: same ballpark, different players; different rules, same score

Gibbons, D. L., & Spencer, J. (2011) · Mucosal Immunology · doi:10.1038/mi.2010.85 · Cited by 170

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets

Kastenmüller, K., Wille-Reece, U., Lindsay, R. W. B., Trager, L. R., Darrah, P. A., Flynn, B. J., Becker, M. R., Udey, M. C., Clausen, B. E., Igyarto, B. Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45416 · Cited by 167

The contribution of immunology to the rational design of novel antibacterial vaccines

Kaufmann, S. H. E. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1688 · Cited by 162

Dendritic cell‐targeted protein vaccines: a novel approach to induce T‐cell immunity

Trumpfheller, C., Longhi, M. P., Caskey, M., Idoyaga, J., Bozzacco, L., Keler, T., Schlesinger, S. J., & Steinman, R. M. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02496.x · Cited by 161

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI)

Taylor, D. N., Treanor, J. J., Strout, C., Johnson, C., Fitzgerald, T., Kavita, U., Ozer, K., Tussey, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.001 · Cited by 160

Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells

Jones, J. C., Turpin, E. A., Bultmann, H., Brandt, C. R., & Schultz-Cherry, S. (2006) · Journal of Virology · doi:10.1128/jvi.01678-06 · Cited by 159

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

Schellack, C., Prinz, K., Egyed, A., Fritz, J. H., Wittmann, B., Ginzler, M., Swatosch, G., Zauner, W., Kast, C., Akira, S., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.071 · Cited by 158

A Methylated Phosphate Group and Four Amide-linked Acyl Chains in Leptospira interrogans Lipid A

Que, N. L. S., Ribeiro, A. A., Kalb, S. R., Cotter, R. J., Bulach, D., Adler, B., Girons, I. S., Werts, C., & Raetz, C. R. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400598200 · Cited by 158

Conjugation of protein to immunostimulatory DNA results in a rapid, long‐lasting and potent induction of cell‐mediated and humoral immunity

Tighe, H., Takabayashi, K., Schwartz, D. H., Marsden, R., Beck, L., Corbeil, J., Richman, D. D., Eiden, J., Spiegelberg, H. L., & Raz, E. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200007)30:7<1939::aid-immu1939>3.0.co;2-# · Cited by 156

Role of Toll‐like receptors in costimulating cytotoxic T cell responses

Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A. M., Sirard, J., Röthlisberger, P., & Bachmann, M. F. (2003) · European Journal of Immunology · doi:10.1002/eji.200323919 · Cited by 155

Self-Adjuvanting Lipopeptide Vaccines

Moyle, P., & Toth, I. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503249 · Cited by 155

Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants

Olive, C. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.189 · Cited by 154

Designing polymeric particles for antigen delivery

Koker, S. D., Lambrecht, B. N., Willart, M. A. M., van Kooyk, Y., Grooten, J., Vervaet, C., Remon, J. P., & Geest, B. G. D. (2010) · Chemical Society Reviews · doi:10.1039/b914943k · Cited by 151

Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults

Treanor, J. J., Taylor, D. N., Tussey, L., Hay, C. M., Nolan, C., Fitzgerald, T. F., Liu, G., Kavita, U., Song, L., Dark, I., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.009 · Cited by 147

Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses

Garaude, J., Kent, A., van Rooijen, N., & Blander, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002868 · Cited by 147

Cholera toxin - a foe & a friend.

Sánchez, J., & Holmgren, J. R. (2011) · PubMed · Cited by 145

CpG-DNA Aided Cross-Priming by Cross-Presenting B Cells

Heit, A., Huster, K. M., Schmitz, F., Schiemann, M., Busch, D. H., & Wagner, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1501 · Cited by 141

Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine

Gahéry‐Ségard, H., Pialoux, G., Muylder, B. C.-D., Sermet, S., Poncelet, H., Raux, M., Tartar, A. L., Lévy, J. P., Gras‐Masse, H., & Guillet, J. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1694-1703.2000 · Cited by 141

Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity

He, L.-Z., Crocker, A., Lee, J., Mendoza-Ramírez, J.-L., Wang, X.-T., Vitale, L. A., O’Neill, T. J., Petromilli, C., Zhang, H., Lopez, J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6259 · Cited by 139

A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials

Burton, D. R., Desrosiers, R. C., Doms, R. W., Feinberg, M. B., Gallo, R. C., Hahn, B. H., Hoxie, J. A., Hunter, E., Korber, B., LANDAY, A. L., et al. (2004) · Science · doi:10.1126/science.1094620 · Cited by 139

History of Vaccine Development

Plotkin, S. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1339-5 · Cited by 135

Structural requirements of the rIn·rCn complex for Induction of human interferon

Carter, W. A., Pitha, P. M., Marshall, L. W., Tazawa, I., Tazawa, S., & Ts’o, P. O. P. (1972) · Journal of Molecular Biology · doi:10.1016/0022-2836(72)90560-8 · Cited by 129

The current challenges for vaccine development

Oyston, P. C. F., & Robinson, K. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.039180-0 · Cited by 123

Respiratory syncytial virus vaccine development

Hurwitz, J. L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.120 · Cited by 119

License to kill: Formulation requirements for optimal priming of CD8+ CTL responses with particulate vaccine delivery systems

Foged, C., Hansen, J. U., & Agger, E. M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.08.016 · Cited by 117

Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs

Song, L., Nakaar, V., Kavita, U., Price, A., Huleatt, J., Tang, J. T., Jacobs, A., Liu, G., Huang, Y., Desai, P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002257 · Cited by 115

Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies

O’Brien, N. W., Jones, S. T., Williams, D. G., Cunningham, H. B., Moreno, K. M., Visentin, B., Gentile, A. M., Vekich, J. A., Shestowsky, W. S., Hiraiwa, M., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900048-jlr200 · Cited by 113

Lipopeptide structure determines TLR2 dependent cell activation level

Buwitt‐Beckmann, U., Heine, H., Wiesmüller, K., Jung, G., Brock, R. E., & Ulmer, A. J. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.05029.x · Cited by 112

Vaccines Against Drug Abuse

Shen, X. Y., Orson, F. M., & Kosten, T. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.281 · Cited by 111

Peptides Identified through Phage Display Direct Immunogenic Antigen to Dendritic Cells

Curiel, T. J., Morris, C. B., Brumlik, M. J., Landry, S. J., Finstad, K., Nelson, A., Joshi, V., Hawkins, C., Alarez, X., Lackner, A. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7425 · Cited by 111

Combination adjuvants: the next generation of adjuvants?

Mutwiri, G., Gerdts, V., den Hurk, S. V. D. L., Auray, G., Eng, N. F., Garlapati, S., Babiuk, L. A., & Potter, A. A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.154 · Cited by 110

A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge

Zhang, X., Chentoufi, A. A., Dasgupta, G., Nesburn, A. B., Wu, M., Zhu, X., Carpenter, D., Wechsler, S. L., You, S., & BenMohamed, L. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.81 · Cited by 110

Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination

Salman, H. H., Irache, J. M., & Gamazo, C. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.091 · Cited by 107

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

Anderson, R. C., Fox, C. B., Dutill, T. S., Shaverdian, N., Evers, T., Poshusta, G. R., Chesko, J., Coler, R. N., Friede, M., Reed, S. G., et al. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.08.022 · Cited by 105

TLR2‐activated human langerhans cells promote Th17 polarization via IL‐1β, TGF‐β and IL‐23

Aliahmadi, E., Gramlich, R., Grützkau, A., Hitzler, M., Krüger, M., Baumgrass, R., Schreiner, M., Wittig, B., Wanner, R., & Peiser, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200838742 · Cited by 103

Computational Design of High-Affinity Epitope Scaffolds by Backbone Grafting of a Linear Epitope

Azoitei, M. L., Ban, Y. A., Julien, J., Bryson, S., Schroeter, A., Kalyuzhniy, O., Porter, J. R., Adachi, Y., Baker, D. A., PAI, E. F., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.10.003 · Cited by 101

TLR5 functions as an endocytic receptor to enhance flagellin‐specific adaptive immunity

Letran, S. E., Lee, S., Atif, S. M., Uematsu, S., Akira, S., & McSorley, S. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201040717 · Cited by 100

TLR–TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-α

Ghosh, T. K., Mickelson, D. J., Solberg, J. C., Lipson, K. E., Inglefield, J. R., & Alkan, Ş. Ş. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.04.006 · Cited by 99

The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens

Fritz, J. H., Brunner, S., Birnstiel, M. L., Buschle, M., von Gabain, A., Mattner, F., & Zauner, W. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.007 · Cited by 99

Microbial Pattern Recognition Receptors Mediate M-Cell Uptake of a Gram-Negative Bacterium

Tyrer, P. C., Foxwell, A. R., Cripps, A. W., Apicella, M. A., & Kyd, J. M. (2005) · Infection and Immunity · doi:10.1128/iai.74.1.625-631.2006 · Cited by 97

Mannosylated Dextran Nanoparticles: A pH-Sensitive System Engineered for Immunomodulation through Mannose Targeting

Cui, L., Cohen, J. A., Broaders, K. E., Beaudette, T. T., & Fréchet, J. M. J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100596w · Cited by 97

Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial

Schmidt, J., Welsch, T., Jäger, D., Mühlradt, P. F., Büchler, M. W., & Märten, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603903 · Cited by 93

Lipopeptide epitopes extended by an N ϵ ‐palmitoyl‐lysine moiety increase uptake and maturation of dendritic cells through a Toll‐like receptor‐2 pathway and trigger a Th1‐dependent protective immunity

Zhu, X., Ramos, T., Gras‐Masse, H., Kaplan, B. E., & BenMohamed, L. (2004) · European Journal of Immunology · doi:10.1002/eji.200425166 · Cited by 93

Boosting antibody responses by targeting antigens to dendritic cells

Caminschi, I., & Shortman, K. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.10.007 · Cited by 89

The potential of 3′,5′-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant

Chen, W., KuoLee, R., & Yan, H. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.081 · Cited by 88

Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin

Talbot, H. K., Rock, M. T., Johnson, C., Tussey, L., Kavita, U., Shanker, A., SHAW, A. R., & Taylor, D. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014442 · Cited by 88

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

Lévy, Y., Durier, C., Lascaux, A., Meiffrédy, V., Gahéry‐Ségard, H., Goujard, C., Rouzioux, C., Resch, M., Guillet, J., Kazatchkine, M. D., et al. (2006) · AIDS · doi:10.1097/01.aids.0000206504.09159.d3 · Cited by 88

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection

Hong, S. H., Byun, Y.-H., Nguyen, C. T., Kim, S. Y., Seong, B. L., Park, S., Woo, G.-J., Yoon, Y., Koh, J. T., Fujihashi, K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.10.058 · Cited by 86

TLR Ligand–Peptide Conjugate Vaccines

Zom, G. G., Khan, S., Filippov, D. V., & OSSENDORP, F. A. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00007-x · Cited by 85

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome

Strayer, D. R., Carter, W. A., Stouch, B. C., Stevens, S. R., Bateman, L., Cimoch, P. J., Lapp, C. W., Peterson, D. L., the Chronic Fatigue Syndrome AMP-516 Study Group, & Mitchell, W. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031334 · Cited by 84

Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells

CEPPELLINI, R., Frumento, G., Ferrara, G. B., TOSI, R. M., Chersi, A., & Pernis, B. (1989) · Nature · doi:10.1038/339392a0 · Cited by 84

Structure−Activity Relationships in Toll-like Receptor-2 Agonistic Diacylthioglycerol Lipopeptides

Wu, W., Li, R., Malladi, S. S., Warshakoon, H. J., Kimbrell, M. R., Amolins, M. W., Ukani, R., Datta, A., & David, S. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901839g · Cited by 79

Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8 + -T-Cell Epitopes Recognized

Gahéry‐Ségard, H., Pialoux, G., Figueiredo, S., Igéa, C., Surénaud, M., Gaston, J., Gras‐Masse, H., Lévy, J. P., & Guillet, J. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11220-11231.2003 · Cited by 78

Intranasal lipopeptide primes lung‐resident memory CD8+ T cells for long‐term pulmonary protection against influenza

Deliyannis, G., Kedzierska, K., Lau, Y. F., Zeng, W., Turner, S. J., Jackson, D. C., & Brown, L. E. (2006) · European Journal of Immunology · doi:10.1002/eji.200535217 · Cited by 77

Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope‐specific B‐, T‐helper and T‐killer cell response

WJESMÜLLER, K., Bessler, W. G., & Jung, G. (1992) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1992.tb00299.x · Cited by 75

A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands

Dowling, D. J., Hamilton, C. M., & O’Neill, S. M. (2008) · Cytokine · doi:10.1016/j.cyto.2007.11.020 · Cited by 74

Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice

Liu, G., Tarbet, E. B., Song, L., Reiserová, L., Weaver, B., Chen, Y., Li, H., Hou, F., Liu, X., Parent, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020928 · Cited by 71

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

Dupont, J., Altclas, J., Lepetic, A., Lombardo, M., Vázquez, V., Salgueira, C., Seigelchifer, M. A., Arndtz, N., Antunez, E., Eschen, K. B. V., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.053 · Cited by 70

TLR2 Promotes Th2/Th17 Responses via TLR4 and TLR7/8 by Abrogating the Type I IFN Amplification Loop

Wenink, M. H., Santegoets, K. C. M., Broen, J. C. A., van Bon, L. G., Abdollahi‐Roodsaz, S., Popa, C. D., Huijbens, R. J. F., Remijn, T., Lubberts, E., van Riel, P. L. C. M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900713 · Cited by 70

Changing the Structural Context of a Functional β-Hairpin

Drakopoulou, E., Zinn‐Justin, S., Guenneugues, M., Gilquin, B., Ménèz, A., & Vita, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.11979 · Cited by 68

Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)

Johnson, D. A., Sowell, C. G., Johnson, C. L., Livesay, M. T., Keegan, D. S., Rhodes, M. J., Ulrich, J. T., Ward, J. R., Cantrell, J. L., & Brookshire, V. G. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00374-1 · Cited by 67

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults

Durier, C., Launay, O., Meiffrédy, V., Saïdi, Y., Salmon, D., Lévy, Y., Guillet, J., Pialoux, G., & Aboulker, J.-P. (2006) · AIDS · doi:10.1097/01.aids.0000222077.68243.22 · Cited by 66

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

Perez, S. A., Kallinteris, N. L., Bisias, S., Tzonis, P., Georgakopoulou, K., Varla-Leftherioti, M., Papamichail, M., Thanos, A., Hofe, E. V., & Baxevanis, C. N. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0085 · Cited by 66

The Capacity To Induce Cross-Presentation Dictates the Success of a TLR7 Agonist-Conjugate Vaccine for Eliciting Cellular Immunity

Oh, J. Z., & Kedl, R. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001892 · Cited by 65

Receptors and ligands implicated in human T cell costimulatory processes

Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.11.009 · Cited by 64

Selection of ganglioside GM1‐binding peptides by using a phage library

Matsubara, T., Ishikawa, D., Taki, T., Okahata, Y., & Sato, T. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00962-x · Cited by 63

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine

Ben-Yedidia, T., & Arnon, R. (1998) · Immunology Letters · doi:10.1016/s0165-2478(98)00073-x · Cited by 60

Structure–Activity Relationships in Toll-Like Receptor 2-Agonists Leading to Simplified Monoacyl Lipopeptides

Agnihotri, G., Crall, B. M., Lewis, T. C., Day, T. P., Balakrishna, R., Warshakoon, H. J., Malladi, S. S., & David, S. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201071e · Cited by 59

A Recombinant Flagellin-Poxvirus Fusion Protein Vaccine Elicits Complement-Dependent Protection Against Respiratory Challenge with Vaccinia Virus in Mice

Delaney, K. N., Phipps, J. P., Johnson, J. B., & Mizel, S. B. (2010) · Viral Immunology · doi:10.1089/vim.2009.0107 · Cited by 59

TLR3 agonists as immunotherapeutic agents

Nicodemus, C. F., & Berek, J. S. (2010) · Immunotherapy · doi:10.2217/imt.10.8 · Cited by 58

Lipopeptides containing 2-(palmitoylamino)-6,7-bis(palmitoyloxy)heptanoic acid: synthesis, stereospecific stimulation of B-lymphocytes and macrophages and adjuvanticity in vivo and in vitro

Metzger, J., Jung, G., Bessler, W. G., Hoffmann, P., Strecker, M., Lieberknecht, A., & Schmidt, U. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00111a008 · Cited by 58

CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein

Braga, C. J. M., Massis, L. M., Sbrogio-Almeida, M. E., de Alencar, B. C., Bargieri, D. Y., Boscardin, S. B., Rodrigues, M. M., & Ferreira, L. C. D. S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.003 · Cited by 57

Immunological Evaluation of Lipopeptide Group A Streptococcus (GAS) Vaccine: Structure-Activity Relationship

Zaman, M., Abdel‐Aal, A. M., Fujita, Y., Phillipps, K. S. M., Batzloff, M. R., Good, M. F., & Tóth, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030146 · Cited by 57

Enhanced Immunogenicity ofPlasmodium falciparumPeptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod

Othoro, C., Johnston, D., Lee, R., Soverow, J. E., Bystryn, J., & Nardin, E. H. (2008) · Infection and Immunity · doi:10.1128/iai.00974-08 · Cited by 57

Intranasal Administration Is an Effective Mucosal Vaccine Delivery Route for Self‐Adjuvanting Lipid Core Peptides Targeting the Group A Streptococcal M Protein

Olive, C., Sun, H. K., Ho, M., Dyer, J., Horváth, A., Tóth, I., & Good, M. F. (2006) · The Journal of Infectious Diseases · doi:10.1086/505580 · Cited by 55

3′,5′-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection

Yan, H., KuoLee, R., Tram, K., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.061 · Cited by 53

Dendritic cell activating peptides induce distinct cytokine profiles

Telusma, G., Datta, S. K., Mihajlov, I., Ma, W., Li, J., Yang, H., Newman, W., Messmer, B. T., Minev, B., Schmidt‐Wolf, I. G. H., et al. (2006) · International Immunology · doi:10.1093/intimm/dxl089 · Cited by 53

Rationally designed strings of promiscuous CD4+ T cell epitopes provide help toHaemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines

Falugi, F., Petracca, R., Mariani, M., Luzzi, E., Mancianti, S., Carinci, V., Melli, M. L., Finco, O., Wack, A., Tommaso, A. D., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200112)31:12<3816::aid-immu3816>3.0.co;2-k · Cited by 52

Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines

Lau, Y. F., Deliyannis, G., Zeng, W., Mansell, A. S., Jackson, D. C., & Brown, L. E. (2006) · International Immunology · doi:10.1093/intimm/dxl114 · Cited by 52

Soluble Proteins Induce Strong CD8+ T Cell and Antibody Responses through Electrostatic Association with Simple Cationic or Anionic Lipopeptides That Target TLR2

Chua, B. Y. L., Pejoski, D., Turner, S. J., Zeng, W., & Jackson, D. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100486 · Cited by 52

Experimental human pneumococcal carriage models for vaccine research

Ferreira, D. M., Jambo, K., & Gordon, S. B. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.06.003 · Cited by 49

Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models

Hood, J. D., Warshakoon, H. J., Kimbrell, M. R., Shukla, N. M., Malladi, S. S., Wang, X., & David, S. A. (2010) · Human Vaccines · doi:10.4161/hv.6.4.10866 · Cited by 49

Structure–activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2

Zaman, M., Abdel‐Aal, A. M., Phillipps, K. S. M., Fujita, Y., Good, M. F., & Tóth, I. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.12.046 · Cited by 48

Toward the Development of Prophylactic and Therapeutic Human Papillomavirus Type-16 Lipopeptide Vaccines

Moyle, P. M., Olive, C., Ho, M., Pandey, M., Dyer, J., Suhrbier, A., Fujita, Y., & Tóth, I. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070287b · Cited by 46

TLR-7 and -8 agonists as vaccine adjuvants

Tomai, M. A., & Vasilakos, J. P. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.26 · Cited by 46

Long-Term Multiepitopic Cytotoxic-T-Lymphocyte Responses Induced in Chimpanzees by Combinations ofPlasmodium falciparumLiver-Stage Peptides and Lipopeptides

BenMohamed, L., Thomas, A. W., & Druilhe, P. (2004) · Infection and Immunity · doi:10.1128/iai.72.8.4376-4384.2004 · Cited by 45

Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant

Cataldi, Á., Yevsa, T., Vilte, D. A., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.07.027 · Cited by 44

Synthesis of a Highly Pure Lipid Core Peptide Based Self-Adjuvanting Triepitopic Group A Streptococcal Vaccine, and Subsequent Immunological Evaluation

Moyle, P. M., Olive, C., Ho, M., Good, M. F., & Tóth, I. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060475m · Cited by 43

Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid‐core peptide technology

Hayman, W. A., Tóth, I., Flinn, N. S., Scanlon, M. J., & Good, M. F. (2002) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2002.01067.x · Cited by 42

HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen

Saenz, R., Souza, C. D. S., Huang, C.-T., Larsson, M., Esener, S. C., & Messmer, D. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.054 · Cited by 42

Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy

Ilk, N., Schumi, C.-T., Bohle, B., Egelseer, E. M., & Sleytr, U. B. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-6 · Cited by 42

Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate

Klinguer, C., David, D., Kouach, M., Wieruszeski, J., Tartar, A. L., Marzin, D. R., Lévy, J. P., & Gras‐Masse, H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00196-6 · Cited by 40

A new cloning system based on the OprI lipoprotein for the production of recombinant bacterial cell wall-derived immunogenic formulations

Basto, A. P., Piedade, J., Ramalho, R., Alves, S. P., Soares, H., Cornélis, P., Martins, C. L. V., & Leitão, A. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.11.006 · Cited by 38

Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus

Tripet, B., Kao, D. J., Jeffers, S. A., Holmes, K. V., & Hodges, R. S. (2006) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.03.019 · Cited by 35

Peptidomimetics: modifying peptides in the pursuit of better vaccines

Croft, N. P., & Purcell, A. W. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.161 · Cited by 35

A novel synthetic adjuvant enhances dendritic cell function

Phillipps, K. S. M., Wykes, M., Liu, X. Q., Brown, M. A., Blanchfield, J. T., & Tóth, I. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.03038.x · Cited by 34

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant

Erdile, L. F., & Guy, B. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00295-2 · Cited by 33

Recent Advances in Microparticle and Nanoparticle Delivery Vehicles for Mucosal Vaccination

McNeela, E. A., & Lavelle, E. C. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_140 · Cited by 32

Design of Three-Component Vaccines against Group A Streptococcal Infections: Importance of Spatial Arrangement of Vaccine Components

Abdel‐Aal, A. M., Zaman, M., Fujita, Y., Batzloff, M. R., Good, M. F., & Tóth, I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1007787 · Cited by 32

Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals

Seth, A., Yasutomi, Y., Jacoby, H., Callery, J. C., Kaminsky, S. M., Koff, W. C., Nixon, D. F., & Letvin, N. L. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/088922200309214 · Cited by 32

Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes

Schulze, K., Olive, C., Ebensen, T., & Guzmán, C. A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.024 · Cited by 31

Method for the synthesis of highly pure vaccines using the lipid core peptide system

Moyle, P. M., Olive, C., Good, M. F., & Tóth, I. (2006) · Journal of Peptide Science · doi:10.1002/psc.815 · Cited by 30

Synthesis of Toll-Like Receptor-2 Targeting Lipopeptides as Self-Adjuvanting Vaccines

Chua, B. Y. L., Zeng, W., & Jackson, D. C. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-419-3_14 · Cited by 30

Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes

Petrov, A. B., Semenov, B. F., Vartanyan, Y. P., et al. (1992) · Infection and Immunity · doi:10.1128/iai.60.9.3897-3903.1992 · Cited by 29

A Modular Approach to Assembly of Totally Synthetic Self-adjuvanting Lipopeptide-based Vaccines Allows Conformational Epitope Building

Zeng, W., Horrocks, K. J., Robevska, G., Wong, C. Y., Azzopardi, K. I., Tauschek, M., Robins-Browne, R. M., & Jackson, D. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.227744 · Cited by 29

A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli

Zeng, W., Azzopardi, K. I., Hocking, D. M., Wong, C. Y., Robevska, G., Tauschek, M., Robins-Browne, R. M., & Jackson, D. C. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.017 · Cited by 28

In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets

Linghua, Z., Xingshan, T., & Fengzhen, Z. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.058 · Cited by 26

Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant

Tran, T. T., Reich, C. F., Alam, M. S., & Pisetsky, D. S. (2003) · Clinical Immunology · doi:10.1016/j.clim.2003.08.012 · Cited by 25

Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis

Calvopiña, M., Barroso, P. A., Marco, J. D., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.023 · Cited by 25

Simple synthetic toll-like receptor 2 ligands

Abdel‐Aal, A. M., Al-Isae, K., Zaman, M., & Tóth, I. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.102 · Cited by 24

Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics

Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655

Peptide-based synthetic vaccines

Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449

Salmonellosis: An Overview of Epidemiology, Pathogenesis, and Innovative Approaches to Mitigate the Antimicrobial Resistant Infections

Lamichhane, B., Mawad, A. M. M., Saleh, M., Kelley, W. G., Harrington, P. J., Lovestad, C. W., Amezcua, J., Sarhan, M. M., El Zowalaty, M. E., Ramadan, H., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13010076 · Cited by 353

Designing spatial and temporal control of vaccine responses

Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316